These drugs are a major breakthrough in terms of efficacy, carry few adverse effects, and are changing the way we take care of FLT3-mutated AML patients for every step of the treatment, from induction to post-aHSCT maintenance. Here, FLT3 is linked to acute myeloid leukemia.